Common bone drug could target hidden HIV
NCT ID NCT07216794
Summary
This study is testing whether alendronate, a medication commonly used for bone health, can reduce the hidden reservoir of HIV in people who are already on effective antiviral therapy. Thirty participants will be randomly assigned to receive either alendronate or a placebo pill, and neither they nor the researchers will know who gets which. The main goal is to see if this approach can shrink the pool of dormant virus that persists even with standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chapel Hill (Site ID: 3201)
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University (Site ID: 2301)
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of California, San Francisco HIV/AIDS (Site ID: 801)
San Francisco, California, 94110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Colorado Hospital (Site ID: 6101)
Aurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh (Site ID: 1001)
Pittsburgh, Pennsylvania, 15213, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.